rubius
therapeutics
announces
dosing
first
patient
relapsed
refractory
acute
myeloid
leukemia
ongoing
phase
clinical
trial
nasdaq
ruby
cambridge
globe
newswire
rubius
therapeutics
nasdaq
ruby
biopharmaceutical
company
genetically
engineering
red
blood
cells
create
entirely
new
class
cellular
medicines
called
red
cell
today
announced
first
patient
acute
myeloid
leukemia
aml
dosed
ongoing
phase
clinical
trial
allogeneic
cellular
therapy
product
candidate
evaluated
treatment
patients
relapsed
refractory
locally
advanced
solid
tumors
relapsed
refractory
aml
ongoing
clinical
study
two
phase
arms
one
solid
tumors
relapsed
refractory
aml
engineered
stimulate
innate
adaptive
immunity
activating
natural
killer
nk
cells
cells
inside
patient
body
generate
potent
immune
response
number
studies
show
nk
cells
exhibit
potent
activity
aml
mechanisms
often
suppress
proper
function
nk
cells
leading
disease
progression
said
christina
coughlin
chief
medical
officer
rubius
therapeutics
nk
cells
restored
full
potential
cytolytic
activity
predicts
better
outcome
patients
aml
designed
replicate
immune
system
function
activating
expanding
patient
nk
cells
body
generate
immune
response
engineered
simultaneously
express
hundreds
thousands
copies
costimulatory
molecule
ligand
cytokine
broadly
stimulate
powerful
arms
immune
system
generate
immunity
despite
advances
management
aml
overall
outcome
patients
relapsed
refractory
disease
remains
quite
poor
due
several
factors
including
lack
disease
response
salvage
therapy
overall
toxicity
therapies
said
alexander
spira
director
virginia
cancer
specialists
research
institute
phase
trial
program
potentially
offers
novel
way
treating
relapsed
refractory
aml
using
body
immune
system
attack
cancer
look
forward
working
rubius
therapeutics
differentiated
approach
treating
acute
myeloid
leukemia
aml
aml
rare
aggressive
cancer
blood
bone
marrow
common
form
acute
leukemia
adults
aml
begins
bone
marrow
often
moves
quickly
blood
areas
body
refractory
aml
occurs
patients
received
treatment
typically
two
rounds
chemotherapy
disease
go
remission
patients
experience
remission
return
leukemia
referred
relapsed
aml
overall
outcome
patients
relapsed
refractory
aml
remains
poor
overall
survival
approximately
percent
limited
therapeutic
options
currently
exist
patients
clinical
trial
rubius
therapeutics
enrolling
patients
phase
open
label
multicenter
multidose
expansion
study
study
contains
two
phase
dose
escalation
arms
one
patients
relapsed
refractory
locally
advanced
solid
tumors
another
patients
relapsed
refractory
acute
myeloid
leukemia
two
phase
arms
determine
safety
tolerability
pharmacokinetics
maximum
tolerated
dose
recommended
phase
dose
dosing
regimen
patients
solid
tumors
well
patients
relapsed
refractory
aml
trial
also
assess
pharmacodynamics
measured
changes
nk
cell
number
function
relative
baseline
activity
patient
populations
study
include
expansion
phase
specified
tumor
types
phase
portion
solid
tumor
arm
extent
pandemic
may
impact
rubius
ability
enroll
patients
trial
depend
future
developments
allogeneic
cellular
therapy
product
candidate
evaluated
treatment
patients
relapsed
refractory
locally
advanced
solid
tumors
relapsed
refractory
acute
myeloid
leukemia
engineered
simultaneously
present
hundreds
thousands
copies
costimulatory
molecule
native
forms
designed
stimulate
innate
adaptive
immunity
activating
nk
cells
cells
inside
patient
body
generate
immune
response
rubius
therapeutics
rubius
therapeutics
nasdaq
ruby
biopharmaceutical
company
genetically
engineering
red
blood
cells
create
entirely
new
class
cellular
medicines
called
red
cell
company
proprietary
red
genetically
engineers
cultures
red
cell
therapeutics
create
selective
potent
allogeneic
cellular
therapies
potential
treatment
cancer
autoimmune
diseases
rubius
initial
product
candidates
designed
activate
expand
immune
system
function
fight
cancer
modulate
immune
system
induce
tolerance
treatment
autoimmune
diseases
rubius
therapeutics
manufacturing
site
recently
named
top
best
places
work
rhode
island
among
companies
providence
business
news
information
visit
follow
us
twitter
linkedin
like
us
facebook
forward
looking
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
amended
including
without
limitation
statements
regarding
expectations
regarding
therapeutic
potential
red
cell
therapeutics
including
treatment
solid
tumors
acute
myeloid
leukemia
strategy
business
plans
focus
words
may
could
would
expect
plan
anticipate
intend
believe
estimate
predict
project
potential
continue
target
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
press
release
based
management
current
expectations
beliefs
subject
number
risks
uncertainties
important
factors
may
cause
actual
events
results
differ
materially
expressed
implied
statements
contained
press
release
including
without
limitation
expectations
regarding
therapeutic
potential
clinical
study
risks
uncertainties
related
development
red
cell
therapeutic
product
candidates
therapeutic
potential
risks
identified
sec
filings
including
quarterly
report
form
quarter
ended
june
subsequent
filings
sec
caution
place
undue
reliance
statements
speak
date
made
disclaim
obligation
publicly
update
revise
statements
reflect
change
expectations
events
conditions
circumstances
statements
may
based
may
affect
likelihood
actual
results
differ
set
forth
statements
statements
contained
press
release
represent
views
date
hereof
relied
upon
representing
views
subsequent
date
explicitly
disclaim
obligation
update
statements
contacts
investors
lori
melan√ßon
vice
president
corporate
communications
investor
relations
media
marissa
hanify
director
corporate
communications
dan
budwick
dan
